|
|
2016 Featured Talks » Towards personalized immunotherapy of HNSCC
Stephen Schoenberger, Part 1 from MCC Industry Relations on Vimeo.
Stephen Schoenberger, part 2 from MCC Industry Relations on Vimeo.
Stephen Schoenberger, PhD
Professor, Division of Cellular Immunology, La Jolla Institute for Allergy and Immunology
Head of Cancer Vaccines, Human Longevity Inc.
Dr. Schoenberger is a Professor in the Laboratory of Cellular Immunology and Chair of LIAI’s Center for the Immunobiology of Cancer, as well as an Adjunct Professor of Medicine in the Division of Hematology and Oncology at the UCSD Moores Cancer Center. He received his Ph.D. in Microbiology and Molecular Genetics from UCLA in 1993 and completed postdoctoral training in Immunohematology and Tumor Immunology at the University of Leiden in The Netherlands. Dr. Schoenberger was appointed to LIAI’s faculty in 1998 as an Assistant Professor, was promoted to Associate Professor in 2002, gained Tenure in 2005, and became a Professor in 2007. He is a recipient of Scholar Awards from both the American Cancer Society and the Leukemia and Lymphoma Society, and is on the editorial advisory board of the Journal of Experimental Medicine.
Dr. Schoenberger is a leader in the immunobiology of CD4+ and CD8+ T cell responses with particular expertise on the generation and maintenance of immune memory by these subsets and in the key role of antigen-presenting cells (APC) in mediating antigen-specific tolerance versus immunity. His research has revealed a new mechanism for how CD4+ T cells provide the ‘help’ necessary for optimal CD8+ T cell responses via APC activation and his laboratory was the first to demonstrate the role of T cell programming in guiding the development of CD8+ T cells. More recently, he has sought to translate his laboratory’s insights into T cell and APC biology for the personalized immunotherapy of cancer based on patient-specific tumor neoantigens in work that will lead to clinical trials at the Moores Cancer Center planned for later in 2016.
|
